NCT02932436 - Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

October 10, 2016

Primary Completion Date

June 15, 2020

Study Completion Date

August 31, 2020

Conditions

Diabetes Mellitus, Type 2Diastolic Dysfunction

Interventions

DRUG

Empagliflozin

10 mg per os daily for 12 weeks

DRUG

Placebo

amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks

Trial Locations (1)

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Zentrum für Kardiologie, Präventive Kardiologie und Medizinische Prävention, Mainz